Q3 Report 2018

Filgotinib, a selective JAK1-inhibitor which has shown activity and favorable tolerability in inflammatory diseases.

Financial highlights

Group revenues

205.1 million

Read more

Cash position

1343.7 million

Read more

Letter from the management

This quarter has been a particularly exciting one for Galapagos, and quite a historical one for our company.
Read more